id: NEW:buprenorphine_naloxone_combination_treatment_to_neonatal_icu_admission_rate
name: Buprenorphine-Naloxone Combination Treatment During Pregnancy â†’ Neonatal ICU Admission Rate
from_node:
  node_id: NEW:buprenorphine_naloxone_combination_treatment
  node_name: Buprenorphine-Naloxone Combination Treatment During Pregnancy
to_node:
  node_id: neonatal_icu_admission_rate
  node_name: Neonatal ICU Admission Rate
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Pregnant individuals receive buprenorphine-naloxone for opioid use disorder treatment'
- 'Step 2: Reduced severity of neonatal abstinence syndrome in exposed newborns'
- 'Step 3: Less intensive monitoring and treatment required for neonatal withdrawal'
- 'Step 4: Fewer newborns require intensive care unit level of care'
- 'Step 5: Modestly lower NICU admission rates among exposed infants'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Loreen Straub et al. 2024. "Comparative Safety of In Utero Exposure to Buprenorphine
    Combined With Naloxone vs Buprenorphine Alone.." https://doi.org/10.1001/jama.2024.11501
  supporting_citations:
  - Additional citations require full-text access - Abstract references limited perinatal safety data
    on combination product
  - Additional citations require full-text access - Study builds on existing buprenorphine monotherapy
    pregnancy research
  - Additional citations require full-text access - Medicaid utilization data from 2000-2018 analyzed
  doi: 10.1001/jama.2024.11501
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Prenatal buprenorphine-naloxone exposure was associated with a 9% lower risk of NICU admission
  compared to buprenorphine alone (absolute risk 30.6% vs 34.9%).
quantitative_effects:
  effect_size:
    value: 0.91
    type: relative_risk
    ci_lower: 0.85
    ci_upper: 0.98
  sample_size: 8695
structural_competency:
  equity_implications: NICU admissions represent significant healthcare resource utilization and family
    disruption. Reducing NICU admissions through optimal medication treatment supports both maternal-infant
    bonding and reduces healthcare system burden. This has equity implications as Medicaid populations
    may face additional barriers to extended NICU stays.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.685133'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
